Compare Invesco DB Commodity Index Tracking Fund (DBC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs GSK plc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $30.09, while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Invesco DB Commodity Index Tracking Fund pays none, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| DBC | GSK | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $61.18 |
52-Week Low | $21.62 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $30.11, up 0.6% with a bullish technical signal from moving averages. The stock shows neutral oscillators with RSI at 59.40, while support and resistance cluster around $30. Recent news highlights commodities ETFs gaining attention as inflation hedges, with articles discussing broad commodity exposure and portfolio strategies.
The outlook for DBC appears cautiously optimistic given technical momentum and commodity market interest. Key risks include commodity price volatility and geopolitical tensions affecting supply chains. Investment opportunity lies in potential inflation hedging benefits, though fundamental metrics remain unavailable for deeper analysis.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
